Literature DB >> 2300248

Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data.

C G Goetz1, C M Tanner, R D Penn, G T Stebbins, D W Gilley, K M Shannon, H L Klawans, C L Comella, R S Wilson, T Witt.   

Abstract

We studied motor and psychomotor changes over 1 year after surgery in 7 patients with severe idiopathic Parkinson's disease (PD) who underwent intrastriatal autologous adrenal medulla transplant. Significant clinical improvements were present 1 year after surgery and primarily involved increased quantity of "on" time and increased quality of "off" time: "on" time increased from a mean 60.7% of the waking day to 82.7%, and "off" function improved. In contrast, although "on" function also improved, statistically significant improvement occurred in only 1 measure, the Unified Parkinson's Disease Rating Scale activities of daily living subscale. Medications did not change, and motor fluctuations persisted. Improvement began several weeks after surgery, was maximal at 4 to 6 months, and was sustained thereafter. There was significant group improvement in quality of life measures of sleep and rest, social isolation, and ambulation. One patient had severe, recurrent depression postoperatively. The efficacy of adrenal transplant surgery is not transient, and specific functional improvements can be prolonged.

Entities:  

Mesh:

Year:  1990        PMID: 2300248     DOI: 10.1212/wnl.40.2.273

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Cell implantation in Parkinson's disease.

Authors:  I Madrazo; M Aguilera; R Franco-Bourland
Journal:  BMJ       Date:  1990-10-13

Review 2.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

Review 3.  Cell-based therapies in Parkinson's disease.

Authors:  Paul Greene
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

4.  Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life.

Authors:  A M Damiano; M M McGrath; M K Willian; C F Snyder; P A LeWitt; P F Reyes; R R Richter; E D Means
Journal:  Qual Life Res       Date:  2000-02       Impact factor: 4.147

Review 5.  A review of health-related quality-of-life concepts and measures for Parkinson's disease.

Authors:  A M Damiano; C Snyder; B Strausser; M K Willian
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

Review 6.  Treatment of Parkinson's disease.

Authors:  M J Aminoff
Journal:  West J Med       Date:  1994-09

7.  Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson's disease.

Authors:  Lori K Smith; Nafisa M Jadavji; Keri L Colwell; S Katrina Perehudoff; Gerlinde A Metz
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

8.  Re-initiated growth from mature ventral mesencephalon: an in oculo transplant study of nigrostriatal co-grafts.

Authors:  I Strömberg; M Johansson
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

Review 9.  Cell-based therapies for Parkinson disease—past insights and future potential.

Authors:  Roger A Barker; Janelle Drouin-Ouellet; Malin Parmar
Journal:  Nat Rev Neurol       Date:  2015-08-04       Impact factor: 42.937

10.  Influences of Chronic Mild Stress Exposure on Motor, Non-Motor Impairments and Neurochemical Variables in Specific Brain Areas of MPTP/Probenecid Induced Neurotoxicity in Mice.

Authors:  Udaiyappan Janakiraman; Thamilarasan Manivasagam; Arokiasamy Justin Thenmozhi; Musthafa Mohamed Essa; Rajamani Barathidasan; Chidambaram SaravanaBabu; Gilles J Guillemin; Mohammed A S Khan
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.